The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

Despite optimal treatment, including renin-angiotensin system (RAS) inhibitors, patients with type 2 diabetic nephropathy have high cardiorenal morbidity and mortality related to residual albuminuria. We evaluated whether or not atrasentan, a selective endothelin A receptor antagonist, further reduc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: de Zeeuw, Dick, Coll, Blai, Andress, Dennis, Brennan, John J., Tang, Hui, Houser, Mark, Correa-Rotter, Ricardo, Kohan, Donald, Lambers Heerspink, Hiddo J., Makino, Hirofumi, Perkovic, Vlado, Pritchett, Yili, Remuzzi, Giuseppe, Tobe, Sheldon W., Toto, Robert, Viberti, Giancarlo, Parving, Hans-Henrik
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Nephrology 2014
Materias:
Clinical Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4005314/
https://ncbi.nlm.nih.gov/pubmed/24722445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2013080830
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares